The tool also can be used on contrasted abdominal scans completed for other clinical indications, helping providers to identify and address suspicious lesions before they worsen.  

The U.S. Department of Justice has formally accused Done Global of unlawfully distributing ADHD medications without medical need, using a subscription program and targeted advertising to find patients searching for drugs. The company is also accused of filing false medical claims to Medicare, Medicaid and commercial insurance. Done's founder and CEO was convicted last month on related charges and awaits sentencing. 

An exclusive report from local NBC affiliate KARE 11 tells the story of Noah Leopold, a man who died after receiving two new hearts. The first deteriorated, and the second one killed him. Now, his family is suing, saying the Mayo Clinic failed to inform them of the risks. The nonprofit health system denies the allegations. 

The biggest investor in a nursing home chain can run but not hide from comeuppance for the chain’s alleged role in harms—including deaths—done to hundreds of patients.

Cytokinetics has secured FDA approval for aficamten, its new drug for the treatment of symptomatic obstructive HCM. Aficamten will be sold under the brand name Myqorzo. 

PAD in patients with diabetes is common and associated with an increased risk of several adverse events. A new guidance from the American College of Cardiology reviewed this topic at length, identifying areas where care needs to improve.

One of the event's primary takeaways was that interventional cardiology does still attract a healthy number of trainees. However, SCAI sees several ways the specialty can improve to be even more appealing in the future. 

PFA has emerged as the preferred ablation strategy for many electrophysiologists, but some questions do remain about its long-term impact. HRS is developing this new registry to be as user-friendly for clinicians as possible.

“Physical AI agents being able to actually deliver some of these services—all the way into robotic surgery—this is where we're going to see this next chapter of medicine be written,” said Kimberly Powell, vice president and general manager of healthcare at Nvidia.
 

The ACC and AHA both issued new statements on noninvasive CCTA offerings that use advanced AI to evaluate patients with suspected CAD. These technologies have gained significant momentum in recent years, and experts agree that they represent a game-changing advancement in the world of cardiovascular imaging.